Table 1 Binding affinity and neutralization potency characterization of the selected NAbs
Antigen specific | mAb | SARS-CoV-2 | SARS-CoV | |||||
|---|---|---|---|---|---|---|---|---|
RBD KD (nM) | Receptor blocking IC50 (ng/ml) | Pesudo virus IC50 (ng/ml) | Authentic virus IC50 (ng/ml) | RBD KD (nM) | Receptor blocking IC50 (μg/ml) | Pesudo virus IC50 (μg/ml) | ||
SARS-CoV-2 specific | 24-2K | 6.1 | 63.4 | 17.0 | 171.0 | N.D. | N.D. | N.D. |
24-1L | 7.3 | 7.0 | 5.1 | 229.0 | N.D. | N.D. | N.D. | |
24-11K | 2.7 | 2.0 | 5.6 | 74.0 | N.D. | N.D. | N.D. | |
24-12K | 2.2 | 7.0 | 8.2 | 162.0 | N.D. | N.D. | N.D. | |
25-C4 | 1.2 | 43.2 | 50.0 | 112.0 | N.D. | N.D. | N.D. | |
25-C5 | 1.0 | 49.0 | 33.0 | 419.0 | N.D. | N.D. | N.D. | |
25-C8 | 2.8 | 68.6 | 68.0 | 345.0 | N.D. | N.D. | N.D. | |
25-C9 | 2.2 | 138.9 | 8.0 | 146.0 | N.D. | N.D. | N.D. | |
25-B5 | 3.5 | 2.0 | 1.0 | 91.0 | N.D. | N.D. | N.D. | |
25-F8 | 4.0 | 79.9 | 8.7 | 345.0 | N.D. | N.D. | N.D. | |
25-G7 | 0.5 | 29.0 | 10.6 | 55.0 | N.D. | N.D. | N.D. | |
26-40K | 6.8 | 2.2 | 4.2 | 21.0 | N.D. | N.D. | N.D. | |
26-34L | 15.9 | 7.0 | 10.0 | 171.0 | N.D. | N.D. | N.D. | |
26-45K | 3.9 | 3.7 | 2.7 | 162.0 | N.D. | N.D. | N.D. | |
28-15L | 2.7 | 7.0 | 35.0 | 171.0 | N.D. | N.D. | N.D. | |
28-8L | 11.9 | 4.1 | 4.0 | 38.0 | N.D. | N.D. | N.D. | |
CB6 | 10.7 | 7.0 | 9.7 | 73.0 | N.D. | N.D. | N.D. | |
Crossing | 25-D9 | 0.4 | 356.1 | 14.0 | 345.0 | 7.2 | 2.2 | 0.9 |
25-F7 | 1.2 | 26.5 | 22.0 | 1883.0 | 4.9 | 5.3 | 5.0 | |
28-26K | 0.1 | 89.3 | 25.0 | 330.0 | 4.9 | 3.8 | 3.5 | |
CR3022 | 57.8 | >15000 | >25000 | N.D. | 0.9 | 1.9 | 0.4 | |
S309 | <1E-3 | >15000 | 60.2 | N.D. | <1E−3 | >15 | 0.03 | |